Helix vs SOPHiA GENETICS (2026)
Two genomics platforms selling to health systems with different units of work. Helix is population scale infrastructure: institutions run programmes on it, sequence once and return to that data for later clinical and research questions, with payers and life sciences as secondary buyers. SOPHiA is analysis infrastructure for the laboratory, applying patented algorithms to call, annotate and interpret variants from sequencing the institution already performs. The choice follows the ambition. A health system enrolling a population and planning to reuse those genomes for a decade is buying what Helix sells, and inherits a consent problem it must solve before the first sample. A laboratory that wants better interpretation on the work it already does is buying what SOPHiA sells, and the commitment is far smaller.
- It is built for population genomics at health system scale, with institutions running programmes on the platform rather than ordering individual tests, and payers and life sciences as adjacent buyers.
- Sequence once and reuse is the architectural argument, which changes the economics of genomics from a per test cost into an asset the institution holds.
- The interoperability position is oriented to enterprise deployment rather than to a laboratory workflow, which is what a population programme actually requires.
- The platform is aimed at the laboratory doing the interpretation, applying patented algorithms to call, annotate and interpret variants across the institution's own sequencing.
- Cloud native delivery with a long established analysis product suits a laboratory that wants capability rather than a programme, and does not require a population scale commitment.
- Public listing brings financial disclosure obligations that matter when a laboratory workflow will depend on the vendor for years.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Helix and SOPHiA GENETICS are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Helix | SOPHiA GENETICS |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2015 | 2011 |
| Headquarters | San Mateo, California | Boston, Massachusetts |
| Website | helix.com | sophiagenetics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Helix its top capability grade on Setting and Specialty Coverage. Set against SOPHiA GENETICS, Helix grades higher on AI Governance and Bias Disclosure and Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards SOPHiA GENETICS its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Helix, SOPHiA GENETICS grades higher on AI Centrality and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Helix or SOPHiA GENETICS?
On the axes where the AI Health Index separates them, Helix grades higher on AI Governance and Bias Disclosure and Setting and Specialty Coverage, and SOPHiA GENETICS grades higher on AI Centrality and Security Certifications and Trust Center. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Helix and SOPHiA GENETICS differ most?
The widest separation the AI Health Index records between Helix and SOPHiA GENETICS is on AI Centrality, where Helix grades C and SOPHiA GENETICS grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Helix and SOPHiA GENETICS grade the same?
The AI Health Index grades Helix and SOPHiA GENETICS the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
Population genomics raises a consent question that neither vendor's material fully resolves and that a health system must answer before either platform is deployed: a sequence generated once and reused for future clinical and research purposes requires a consent model that anticipates uses not yet defined, and participants cannot revoke a genome once it is shared.
Ancestral representation applies to both, since interpretation quality depends on reference data drawn disproportionately from European ancestry populations. Neither publishes pricing in a form that allows comparison, and the commercial shapes differ enough, per programme against per analysis, that a like for like figure will not exist.